Wells Fargo: Maintaining the Biomarin Pharmaceutical (BMRN.US) rating, adjusted from an increase holdings to an increase rating, and the target price was adjusted from $100.00 to $110.00.
富国银行：维持Biomarin Pharmaceutical(BMRN.US)评级，由增持调整至增持评级, 目标价由100.00美元调整至110.00美元。
Wells Fargo: Maintaining the Biomarin Pharmaceutical (BMRN.US) rating, adjusted from an increase holdings to an increase rating, and the target price was adjusted from $100.00 to $110.00.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.